Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated:  3/4/2016
Kellogg Pharmacy - Evanston Hospital
mi
from
Evanston, IL
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated: 3/4/2016
Kellogg Pharmacy - Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated:  3/4/2016
NorthShore University HealthSystem
mi
from
Evanston, IL
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated: 3/4/2016
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated:  3/4/2016
Kellogg Cancer Care Center
mi
from
Glenview, IL
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated: 3/4/2016
Kellogg Cancer Care Center
mi
from
Glenview, IL
Click here to add this to my saved trials
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated:  3/4/2016
Hematology Oncology Associates of Central New York PC
mi
from
East Syracuse, NY
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated: 3/4/2016
Hematology Oncology Associates of Central New York PC
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated:  3/4/2016
Gabrail Cancer Center
mi
from
Canton, OH
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated: 3/4/2016
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated:  3/4/2016
Cleveland Clinic
mi
from
Cleveland, OH
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated: 3/4/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated:  3/4/2016
Taussig Cancer Institute
mi
from
Cleveland, OH
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated: 3/4/2016
Taussig Cancer Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated:  3/4/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Safety Study of TAK-700 in Subjects With Prostate Cancer.
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Status: Enrolling
Updated: 3/4/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated:  3/7/2016
VA Medical Center, San Francisco
mi
from
San Francisco, CA
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated: 3/7/2016
VA Medical Center, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated:  3/7/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated: 3/7/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated:  3/7/2016
VA Medical Center
mi
from
Durham, NC
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated: 3/7/2016
VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated:  3/7/2016
Center for Health Equity Research and Promotion
mi
from
Pittsburgh, PA
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated: 3/7/2016
Center for Health Equity Research and Promotion
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated:  3/8/2016
University Suburban Health Center
mi
from
Cleveland, OH
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated: 3/8/2016
University Suburban Health Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated:  3/8/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated: 3/8/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated:  3/8/2016
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer
Status: Enrolling
Updated: 3/8/2016
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients
Status: Enrolling
Updated:  3/10/2016
New York University Cancer Center
mi
from
New York, NY
PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients
Status: Enrolling
Updated: 3/10/2016
New York University Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Florida Cancer Specialists
mi
from
Fort Myers, FL
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Integrated Community Oncology Network, LLC
mi
from
Jacksonville, FL
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Integrated Community Oncology Network, LLC
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Consultants in Blood Disorders and Cancer
mi
from
Louisville, KY
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Consultants in Blood Disorders and Cancer
mi
from
Louisville, KY
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Consultants in Medical Oncology and Hematology, PC
mi
from
Drexel Hill, PA
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Consultants in Medical Oncology and Hematology, PC
mi
from
Drexel Hill, PA
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Associates in Hematology Oncology
mi
from
Chattanooga, TN
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Associates in Hematology Oncology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Phase I/II Evaluation of Cancer-Specific Imaging Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Status: Enrolling
Updated:  3/11/2016
St.Luke's-Roosevelt Hospital Center
mi
from
New York, NY
Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Phase I/II Evaluation of Cancer-Specific Imaging Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Status: Enrolling
Updated: 3/11/2016
St.Luke's-Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status: Enrolling
Updated:  3/15/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status: Enrolling
Updated: 3/15/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status: Enrolling
Updated:  3/15/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status: Enrolling
Updated: 3/15/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status: Enrolling
Updated:  3/15/2016
Lahey Clinic
mi
from
Burlington, MA
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status: Enrolling
Updated: 3/15/2016
Lahey Clinic
mi
from
Burlington, MA
Click here to add this to my saved trials
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status: Enrolling
Updated:  3/15/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status: Enrolling
Updated: 3/15/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease
Status: Enrolling
Updated:  3/15/2016
Houston Methodist
mi
from
Houston, TX
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease
Status: Enrolling
Updated: 3/15/2016
Houston Methodist
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
Phase II Study of Xyotax in Advanced Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
Phase II Study of Xyotax in Advanced Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
Phase II Trial to Assess the Activity of Ketoconazole and Mitoxantrone Plus GM-CSF in Patients With Progressive Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
Phase II Trial to Assess the Activity of Ketoconazole and Mitoxantrone Plus GM-CSF in Patients With Progressive Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  3/15/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 3/15/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
Phase II Study of Patients With Hormone-Naïve Prostate Cancer With a Rising Prostate Specific Antigen: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Thalidomide Plus Docetaxel
Status: Enrolling
Updated:  3/15/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
Phase II Study of Patients With Hormone-Naïve Prostate Cancer With a Rising Prostate Specific Antigen: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Thalidomide Plus Docetaxel
Status: Enrolling
Updated: 3/15/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
A Phase II Trial to Assess the Activity of MVA 5T4 (Trovax®) Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
A Phase II Trial to Assess the Activity of MVA 5T4 (Trovax®) Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
Phase II Trial of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
Phase II Trial of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Southern Cancer Center
mi
from
Mobile, AL
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Southern Cancer Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Marsha G. Fink, Md, Inc.
mi
from
Fountain Valley, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Marsha G. Fink, Md, Inc.
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
VA San Diego Healthcare System
mi
from
San Diego, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
VA San Diego Healthcare System
mi
from
San Diego, CA
Click here to add this to my saved trials